CD19 and neoplasm: Although they are revolutionary in treating CD19 + malignancies, single-target CAR-T cells are associated with several setbacks, such as antigen escape (occurring in 30–60% of B-ALL patients [24]), tumor heterogeneity, and on-target/off-tumor toxicity [25].